ReviewAmerican journal of translational research2025
Mechanism of action and research advancements of Qi-tonifying traditional Chinese medicine in the treatment of type 2 diabetic mellitus.
Review in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Type 2 diabetes mellitus (T2DM) is a metabolic disorder marked by persistent hyperglycemia, potentially leading to irreversible organ damage and posing significant risks to patients' health and life. The prevailing treatments for T2DM consist of oral medications and insulin injections; nonetheless, they are constrained by numerous adverse reactions, drug resistance, and a singular mechanism of action. Qi-tonifying traditional Chinese medicine (QTTCM) is efficacious in the prevention and treatment of T2DM. Research indicates that QTTCM primarily modulates the PI3K/Akt, Insulin Receptor Substrate 1 (IRS-1)/phosphatidylinositol 3-Kinase(PI3K)/Protein kinase B(Akt), glucose transporter (GLUT) and Activated Protein Kinase (AMPK) pathways to enhance the proliferation of pancreatic islet β-cells, restore their functionality, ameliorate insulin resistance (IR), rectify disturbances in glucose and lipid metabolism, mitigate oxidative stress, and suppress inflammation. Consequently, QTTCM sustains glucose homeostasis in patients with T2DM through multiple pathways and targets, thereby improving the pathological state of slow metabolism, which is advantageous for the prevention and treatment of T2DM. QTTCM exerts a beneficial therapeutic impact on T2DM by sustaining glucose homeostasis and enhancing metabolic rate in T2DM patients via many pathways and targets.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.